Endpoints: How Do We Get a Drug to Market?
Plenary Moderator: Joe Stavas, Senior Vice President of Clinical Development, ProKidney
9:00 am Drug Development Considerations for Kidney Diseases: A Regulatory Update
9:30 am Phase 2a Results, Phase 2b Study Design, & Investigations into the Mechanism of Action of Verinurad, a URAT1 Inhibitor, in Development for CKD & Heart Failure
10:00 am Selective ETA receptor antagonist ATRASENTAN for the Treatment of Primary Glomerular Diseases
10:30 am Morning Break & Networking
Forward Thinking Questions to Shape the Next Generation of Drug Development Decisions
Translational Drug Development Track
Track Moderator: Julie Williams, Director/Science Lead Bioscience Rena, AstraZeneca
Track Moderator: Julie Williams, Director/Science Lead Bioscience Rena, AstraZeneca
Harnessing AI to Maximize Data Interrogation for Drug Discovery & Validation
11:00 am Use of Artificial Intelligence in CKD Drug Discovery & Disease Understanding
11:30 am Use of Human Genetics, Biomarkers & AI to Drive Target Discovery & Validation
12:00 pm Using twoXAR’s AI-platform for the Discovery & Preclinical Validation of Therapeutic Leads with Novel MOAs for CKD
Clinical Drug Development Track
Track Moderator: Kevin Fowler, President, The Voice of the Patient
Track Moderator: Kevin Fowler, President, The Voice of the Patient